Search results
Results from the WOW.Com Content Network
The secondary structural features of IL-13 are similar to that of Interleukin 4 (IL-4); however it only has 25% sequence identity to IL-4 and is capable of IL-4 independent signaling. [ 7 ] [ 4 ] [ 8 ] IL-13 is a cytokine secreted by T helper type 2 (Th2) cells, CD4 cells, natural killer T cell , mast cells , basophils , eosinophils and ...
IL-13 is thought to induce the expression of another signalling protein, periostin, by epithelial cells of the bronchi. Periostin in turn seems to partake in a number of asthma related problems, such as bronchial hyperresponsiveness , inflammation, and activation and proliferation of airway fibroblasts , which are involved in airway remodelling.
The interleukin-13 receptor is a type I cytokine receptor, binding Interleukin-13.It consists of two subunits, encoded by IL13RA1 and IL4R, respectively. [1] [2] These two genes encode the proteins IL-13Rα1 and IL-4Rα.
Interleukin 13 receptor, alpha 1, also known as IL13RA1 and CD213A1 (cluster of differentiation 213A1), is a human gene. [5] The protein encoded by this gene is a subunit of the interleukin 13 receptor. This subunit forms a receptor complex with IL4 receptor alpha, a subunit shared by IL13 and IL4 receptors.
Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery.It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may ...
In December 2020, Anakinra was approved by the US Food and Drug Administration for the treatment of deficiency of the interleukin-1–receptor antagonist (DIRA), a rare autoinflammatory disease of infancy. [15] In 2021, it was announced that the Ministry of Health of the Russian Federation had approved the use of Anakinra for the treatment of ...
European Union approval was granted in February 2017. [8] Despite widespread expectations that the FDA would approve baricitinib for rheumatoid arthritis, [24] in April 2017, the FDA issued a rejection, citing concerns about dosing and safety. [25] [26] In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid ...
Tildrakizumab, sold under the brand name Ilumya among others, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. [4] It is approved for the treatment of adults with moderate-to-severe plaque psoriasis in the United States and in the European Union.